but no clear specific mechanism of action. It appears to be a mild monoamine oxidase inhibitor, a mild serotonin reuptake blocker, and consist of other psychotropic compounds and actions yet to be ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

The SARS-CoV-2 pandemic interrupted much respiratory research. Respiratory clinical academics joined colleagues in providing clinical care, and global research efforts were directed to finding new ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

In summary, enalapril significantly mitigated multiple pathological markers associated with aging, including lipid droplets, amyloid, glycogen deposition, and fibrosis, in the brain, kidneys, liver, ...

including ACE inhibitors and ARBs. About 3,500 adults across 28 countries were enrolled in the trial, which started in 2019 and followed participants for an average of about 3 years. The new ...

ACE inhibitors keep the body ... medication is called a direct renin inhibitor (DRI). DRIs block a chemical in your body called renin. This action helps widen your blood vessels, which lowers ...

The authors of the original publication speculated on several possible mechanisms for this ... been on either a diuretic or an angiotensin-converting enzyme inhibitor. Such therapy, although ...